Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionCIBC Asset Management Inc
Latest Disclosed Ownership106,893 shares
Latest Disclosed Value $ 47,732,000
CIBC Asset Management Inc reports 0.69% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 12, 2026 - CIBC Asset Management Inc filed a 13F-HR form disclosing ownership of 106,893 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $47,732,000 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 107,641 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -0.69% during the quarter. The current value of the position is $47,218,914 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 106,893 -748 -0.69 47,732 -2.19 0.1167
2026-02-10 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 107,641 26,636 32.88 48,800 53.83 0.1178
2025-10-31 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 81,005 19 0.02 31,725 -12.01 0.0919
2025-08-14 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 80,986 -4,393 -5.15 36,055 -12.90 0.1115
2025-05-13 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 85,379 888 1.05 41,393 21.66 0.1374
2025-01-31 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 84,491 4,389 5.48 34,025 -8.67 0.1115
2024-11-06 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 80,102 4,432 5.86 37,254 5.03 0.1209
2024-08-01 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 75,670 -674 -0.88 35,468 11.14 0.1262
2024-05-09 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 76,344 4,236 5.87 31,913 8.77 0.1107
2024-02-13 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 72,108 7 0.01 29,340 17.02 0.1096
2023-10-30 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 72,101 7,169 11.04 25,072 9.72 0.1039
2023-08-14 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 64,932 -376 -0.58 22,850 11.05 0.0876
2023-05-12 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 65,308 847 1.31 20,577 10.53 0.0816
2023-02-13 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 64,461 -1,577 -2.39 18,615 -2.65 0.0782
2022-11-03 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 66,038 3,115 4.95 19,121 7.84 0.0839
2022-08-09 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 62,923 -4,664 -6.90 17,731 0.53 0.0719
2022-05-06 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 67,587 -55 -0.08 17,638 18.74 0.0619
2022-02-08 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 67,642 6,305 10.28 14,854 33.51 0.0544
2021-11-09 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 61,337 4,109 7.18 11,126 -3.58 0.0448
2021-08-16 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 57,228 2,690 4.93 11,539 -1.54 0.0467
2021-05-14 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 54,538 6,965 14.64 11,720 4.24 0.0498
2021-02-03 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 47,573 3,021 6.78 11,243 -7.26 0.0529
2020-11-05 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 44,552 6,032 15.66 12,123 8.41 0.0618
2020-07-28 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 38,520 1,144 3.06 11,183 25.74 0.0656
2020-04-30 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 37,376 664 1.81 8,894 10.65 0.0629
2020-02-14 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 36,712 1,421 4.03 8,038 34.44 0.0454
2019-10-30 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 35,291 -183 -0.52 5,979 -8.09 0.0351
2019-08-05 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 35,474 987 2.86 6,505 2.54 0.0389
2019-05-06 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 34,487 -22 -0.06 6,344 10.95 0.0393
2019-02-12 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 34,509 601 1.77 5,718 -12.50 0.0420
2018-11-02 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 33,908 627 1.88 6,535 15.54 0.0404
2018-08-09 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 33,281 1,986 6.35 5,656 10.90 0.0353
2018-04-30 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 31,295 -247 -0.78 5,100 7.89 0.0331
2018-02-02 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 31,542 -310 -0.97 4,727 -2.40 0.0289
2017-11-06 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 31,852 641 2.05 4,843 20.41 0.0303
2017-07-27 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 31,211 977 3.23 4,022 21.66 0.0278
2017-05-12 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 30,234 531 1.79 3,306 51.10 0.0227
2017-02-08 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 29,703 415 1.42 2,188 -14.33 0.0157
2016-10-19 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 29,288 -1,924 -6.16 2,554 -4.88 0.0188
2016-08-02 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 31,212 511 1.66 2,685 10.04 0.0202
2016-05-09 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 30,701 709 2.36 2,440 -35.35 0.0183
2016-02-02 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 29,992 13 0.04 3,774 20.88 0.0311
2015-11-03 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 29,979 397 1.34 3,122 -14.54 0.0250
2015-08-06 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 29,582 1,341 4.75 3,653 9.63 0.0254
2015-05-08 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 28,241 2,054 7.84 3,332 7.10 0.0236
2015-02-10 2014-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 26,187 -6,798 -20.61 3,111 -16.03 0.0207
2014-11-05 2014-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 32,985 -122 -0.37 3,705 18.18 0.0221
2014-08-01 2014-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 33,107 -1,022 -2.99 3,135 29.87 0.0178
2014-05-09 2014-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 34,129 4,954 16.98 2,414 11.35 0.0142
2014-02-04 2013-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 29,175 709 2.49 2,168 0.46 0.0133
2013-10-29 2013-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 28,466 17,889 169.13 2,158 154.78 0.0138
2013-10-02 2013-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 10,577 10,577 847 0.0058
2013-08-09 2013-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 10,577 847 0.0058
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.